CompoAtlas

Panda Vita Camomille matricaire Passiflore Basilic sacré bio

Food supplement declared in France, declaration No 2020-3-722

Panda Vita Camomille matricaire Passiflore Basilic sacré bio, from PANDA SAS, is a food supplement declared in France. Status: earlier declaration, replaced by the 2022 declaration. Main ingredients: Matricaria chamomilla 200 mg per day, Passiflora edulis 200 mg per day, Ocimum tenuiflorum 100 mg per day, Fibres solubles d'acacia. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
PANDA SAS
Status
Earlier declaration, replaced by the 2022 declaration : Panda Vita Camomille matricaire Passiflore Basilic sacré bio
Form
Capsule
Daily dose
2 gélules
Directions for use
2 gélules/jour
Not recommended (according to the manufacturer)
Prolonged use

Declaration 301051, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Matricaria chamomilla L.FlowerPowder (dried or ground plant)200 mg
Passiflora edulis SimsAerial partsPowder (dried or ground plant)200 mg
Ocimum tenuiflorum L.LeafDry aqueous extract100 mg

Other active ingredients

NamePer day
Fibres solubles d'acacianot declared

Additives

E464

Other ingredients

maltodextrine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

L’usage prolongé est déconseillé.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Matricaria chamomilla L.
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • Ocimum tenuiflorum L.
    Read the warning, when it applies and the studies cited

    HOLY BASIL - OCIMUM TENUIFLORUM - SEED

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular condition (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Condition of application: Relief of cough; Digestive aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 February 2026

    HOLY BASIL - OCIMUM TENUIFLORUM - LEAF

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (WHO 2002).

    Sources cited by Health Canada (2)
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a heart condition or diabetes (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Condition of application: Relief of cough/cold/respiratory mucus buildup; Digestive aid; Adaptogen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant (Prakash et al. 2005; Ahmed et al. 2002; WHO 2002; Wohlmuth 2002; Kapoor 2001).

    Sources cited by Health Canada (6)
    • Ahmed A, Ahamed RN, Aladakatti RH, Ghoseawar MG. Reversible antifertility effect of benzene extract of Ocimum sanctum on sperm parameters and fructose content in rats. Journal of basic and clinical physiology and pharmacology 2002;13:51-59. PubMed
    • Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
    • Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian Journal of Physiology and Pharmacology 2005;49(2):125-131. PubMed Review article
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • Wohlmuth H. Sacred basil - an Ayurvedic adaptogen. Botanical Pathways, 2002; Issue 11.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Health Canada monograph dated 27 February 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line